Avidity Biosciences, Inc. (NASDAQ:RNA) Given Average Rating of “Buy” by Brokerages
Avidity Biosciences, Inc. (NASDAQ:RNA – Get Free Report) has earned a consensus recommendation of “Buy” from the thirteen research firms that are covering the firm, MarketBeat Ratings reports. Thirteen analysts have rated the stock with a buy rating. The average 1 year price target among brokers that have updated their coverage on the stock in […]
Avidity Biosciences, Inc. (NASDAQ:RNA – Get Free Report) has earned a consensus recommendation of “Buy” from the thirteen research firms that are covering the firm, MarketBeat Ratings reports. Thirteen analysts have rated the stock with a buy rating. The average 1 year price target among brokers that have updated their coverage on the stock in […]
